Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Early tPA Treatment and Aeromedical Transport of Patients with Acute Myocardial Infarction

Early tPA Treatment and Aeromedical Transport of Patients with Acute Myocardial Infarction Over a 2‐year period 192 patients with acute myocardial infarction (AMI) were transported by helicopter and treated with recombinant tissue‐plasminogen activator (tPA). All patients were entered into the Thrombolysis in Myocardial Infarction‐Phase II (TIMI II) trial. Eighty‐two of these patients were treated with tPA after aeromedical transport to a tertiary care center. One hundred ten patients had tPA treatment initiated by the flight crew prior to transport. The flight crews initiated therapy 28 ± 11 minutes after arrival at the sending hospital. The post‐flight treated patients received the tPA bolus 82 ± 20 minutes after arrival at the sending hospital (P < .0001), and 41 ± 18 minutes after arrival at the receiving hospital (P < .0001). Based on enzyme and electrocardiographic changes, all patients in the study had a confirmed diagnosis of AMI before discharge. Patients with inferior myocardial infarction (MI) treated with tPA in‐flight were more likely to suffer from bradycardia and hypotension requiring atropine injection during transport than the post‐flight treated patients or inflight treated patients with anterior MI. There was no in‐flight mortality in either group. Our experience indicates that patients with AMI can be transported safely during tPA therapy. Also, a trained team whose sole responsibility is the early evaluation and initiation of therapy in a patient with AMI can function as accurately and significantly more rapidly than tertiary care emergency department and ICU personnel following identical protocols. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Early tPA Treatment and Aeromedical Transport of Patients with Acute Myocardial Infarction

Download PDF
9 pages

Loading next page...
 
/lp/wiley/early-tpa-treatment-and-aeromedical-transport-of-patients-with-acute-GB2d240beW

References (13)

Publisher
Wiley
Copyright
Copyright © 1991 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.1991.tb01016.x
Publisher site
See Article on Publisher Site

Abstract

Over a 2‐year period 192 patients with acute myocardial infarction (AMI) were transported by helicopter and treated with recombinant tissue‐plasminogen activator (tPA). All patients were entered into the Thrombolysis in Myocardial Infarction‐Phase II (TIMI II) trial. Eighty‐two of these patients were treated with tPA after aeromedical transport to a tertiary care center. One hundred ten patients had tPA treatment initiated by the flight crew prior to transport. The flight crews initiated therapy 28 ± 11 minutes after arrival at the sending hospital. The post‐flight treated patients received the tPA bolus 82 ± 20 minutes after arrival at the sending hospital (P < .0001), and 41 ± 18 minutes after arrival at the receiving hospital (P < .0001). Based on enzyme and electrocardiographic changes, all patients in the study had a confirmed diagnosis of AMI before discharge. Patients with inferior myocardial infarction (MI) treated with tPA in‐flight were more likely to suffer from bradycardia and hypotension requiring atropine injection during transport than the post‐flight treated patients or inflight treated patients with anterior MI. There was no in‐flight mortality in either group. Our experience indicates that patients with AMI can be transported safely during tPA therapy. Also, a trained team whose sole responsibility is the early evaluation and initiation of therapy in a patient with AMI can function as accurately and significantly more rapidly than tertiary care emergency department and ICU personnel following identical protocols.

Journal

Journal of Interventional Cardiology – Wiley

Published: Jun 1, 1991

There are no references for this article.